Kiniksa Pharmaceuticals announced positive data from the phase 3 RHAPSODY trial evaluating rilonacept for the treatment of recurrent pericarditis. Kiniksa Pharmaceuticals announced positive data from ...

Adult- SC- The recommended loading dose is 160mg twice a day in different sites. Maintenance: 160 mg as single 2 mL injections. Child- SC- The recommended loading dose is 4.4mg/kg. Caution should be ...

Rilonacept is an interleukin-1 (IL-1) blocker, prescribed for Cryopyrin-Associated Periodic Syndromes ((CAPS) - inherited auto-inflammatory conditions) including Familial Cold Autoinflammatory ...

PHILADELPHIA — Rilonacept in patients with recurrent pericarditis led to improvements in clinical and patient-reported measures as soon as after the first injection, according to data presented at the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

June 6, 2011 (London, United Kingdom) — Rilonacept, an interleukin 1 (IL-1) inhibitor, prevented gout flares to a greater extent in patients receiving uric acid–lowering therapy (specifically, ...

HAMILTON, Bermuda, July 16, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and ...

A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1, significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of ...

January 6, 2012 — Gout attacks that can occur during the early stages of urate-lowering therapy may reduce the patient's enthusiasm for continuing long-term treatment, but can be nearly eliminated by ...

The US Food and Drug Administration has approved rilonacept (Arcalyst; Kiniksa Pharmaceuticals), an interleukin-1 inhibitor, for the treatment of recurrent pericarditis and to reduce the risk of ...

Regeneron's ARCALYST® (rilonacept) Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-Lowering Therapy Proportion of patients experiencing gout flares ...

HealthDay News—The use of rilonacept significantly reduces gout flare-ups in the first few months following initiation of urate-lowering therapy (ULT), according to research published online Jan. 4 in ...